Tositumomab: Difference between revisions
→top: '''Iodine I 131 Tositumomab''' |
add better description of mAb with source |
||
| Line 36: | Line 36: | ||
| molecular_weight = 143859.7 g/mol |
| molecular_weight = 143859.7 g/mol |
||
}} |
}} |
||
'''Tositumomab''' |
'''Tositumomab''' is a murine IgG2a lambda monoclonal antibody directed against the [[CD20]] antigen, produced in mammalian cells.<ref name=Label> GlaxoSmithKline and FDA> [http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125011s0126lbl.pdf Bexxar label. Last updated August 2012. Page accessed January 18, 2016</ref> Combined with [[radioisotope]] [[iodine 131]]<ref name=Timmerman2013/> it was called |
||
'''Iodine I 131 Tositumomab''' and was approved for the treatment of relapsed or [[chemotherapy]]/[[rituxan]]-[[refractory]] [[Non-Hodgkin lymphoma]] in 2003.<ref>New York Times. July 1, 2003 [http://www.nytimes.com/2003/07/01/business/company-news-corixa-and-glaxo-s-cancer-drug-wins-fda-approval.html Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval]</ref><ref>[http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/tosicor062703L.htm Product Approval Information - Licensing Action]</ref> |
'''Iodine I 131 Tositumomab''' and was approved for the treatment of relapsed or [[chemotherapy]]/[[rituxan]]-[[refractory]] [[Non-Hodgkin lymphoma]] in 2003.<ref>New York Times. July 1, 2003 [http://www.nytimes.com/2003/07/01/business/company-news-corixa-and-glaxo-s-cancer-drug-wins-fda-approval.html Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval]</ref><ref>[http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/tosicor062703L.htm Product Approval Information - Licensing Action]</ref> |
||
Revision as of 19:54, 18 January 2016
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD20 |
| Clinical data | |
| Trade names | Bexxar |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a609013 |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6416H9874N1688O1987S44 |
| Molar mass | 143859.7 g/mol g·mol−1 |
  (what is this?) (verify) | |
Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, produced in mammalian cells.[1] Combined with radioisotope iodine 131[2] it was called Iodine I 131 Tositumomab and was approved for the treatment of relapsed or chemotherapy/rituxan-refractory Non-Hodgkin lymphoma in 2003.[3][4]
It was sold in the U.S. and Canada under the trade name Bexxar.
This drug combination was developed by Corixa which was purchased by GlaxoSmithKline) in 2005.[5]
Sale of Bexxar was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.[2][6]
References
- ^ GlaxoSmithKline and FDA> [http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125011s0126lbl.pdf Bexxar label. Last updated August 2012. Page accessed January 18, 2016
- ^ a b "Why Good Drugs Sometimes Fail: The Bexxar Story".
- ^ New York Times. July 1, 2003 Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval
- ^ Product Approval Information - Licensing Action
- ^ Carla Mozee for MarketWatch. April 29, 2005 Glaxo to acquire Corixa for $300 million
- ^ Notice by the Food and Drug Administration on October 23, 2013. GlaxoSmithKline LLC; Withdrawal of Approval of the Indication for Treatment of Patients With Relapsed or Refractory, Low Grade, Follicular, or Transformed CD20 Positive Non-Hodgkin's Lymphoma Who Have Not Received Prior Rituximab; BEXXAR
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |